- Target disease: Chagas
- Partners (since project start): Centre for Drug Candidate Optimisation (CDCO)/Monash University, Australia; Epichem, Australia; Murdoch University, Australia; Federal University of Ouro Preto (UFOP), Brazil; Institut Pasteur Korea (IPK), Korea
- Leadership: Head Drug Discovery: Eric Chatelain; Project Coordinator: Delphine Launay.
- Project start: December 2011
- Funding (since project start): Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International; National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID), USA; Spanish Agency for International Development Cooperation (AECID), Spain; Swiss Agency for Development and Cooperation (SDC), Switzerland; Other private foundations and individuals.
- Project status: Completed.
Two interesting candidates from the fenarimol series of compounds were identified through lead optimization efforts. In 2013, the project was in its non-regulatory preclinical phase, with further profiling of candidates, before nominating one candidate for progression into regulatory pre-clinical development. The objective was to perform Good Laboratory Practice (GLP) safety studies, as well as Chemistry, Manufacturing, and Control (CMC) studies on the selected candidate compound, in order to file a formal investigational new drug (IND) application and move the candidate to first-in-man studies. However, given the lack of sustained efficacy of azoles (E1224 and posaconazole) in clinical trials for Chagas diseases, this project has been stopped.
Last update: September 2014